In hematological malignancies, theranostics is particularly promising due to the high expression of disease-specific antigens (e.g., Cluster of Differentiation (CD)20, CD38, CD45, CD123) that can serve as molecular targets for radiopharmaceuticals. Here, CD38 is linked to hematologic disorder.